stella
beta
Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma — Stella
Recruiting
Back to Melanoma trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
United States
Huntsman Cancer Institute, Salt Lake City, Utah
View full record on ClinicalTrials.gov